LED Therapy for the Treatment of Concussive Brain Injury
This trial is active, not recruiting.
|Treatment||medx health console model 1100|
|Sponsor||Boston Children’s Hospital|
|Collaborator||United States Department of Defense|
|Start date||September 2012|
|End date||May 2016|
|Trial size||48 participants|
|Trial identifier||NCT02383472, IRB-P00002527|
A double blind randomized trial of light-emitting diode (LED) therapy for patients suffering from mild traumatic brain injury (mTBI). Patients seen in the Sports Concussion Clinic with cognitive symptoms lasting for greater than 4 weeks will be randomized to either placebo therapy (controls) or treatment with LED therapy (cases). Both cases and controls would complete post-concussion symptom scales Delis-Kaplan Executive Function System (D-KEFS), and ImPACT studies on entry into the study and at weeks 3 and 6, or earlier if their symptoms resolve before the end of the 6 week period.
|Endpoint classification||efficacy study|
|Intervention model||parallel assignment|
|Masking||double blind (subject, caregiver, investigator, outcomes assessor)|
ImPACT Score mean difference
time frame: 6 weeks
Means total post concussion symptom scale score
time frame: 3 to 6 weeks
Male or female participants at least 11 years old.
Inclusion Criteria: - Patients 11 years old or greater - Diagnosed with a concussion whose symptoms have persisted for more than 4 weeks - Total score on the cognitive components of the post-concussion symptom scale exceeds 9, or if they have a composite score on any one of the 4 main outputs of the computerized neurocognitive assessment: Immediate Post-concussion Assessment and Cognitive Testing (ImPACT) that is below the 90th percentile for their age. Exclusion Criteria: - Clinically indicated imaging has been obtained where a hemorrhage is demonstrated - Being considered for an alternate diagnosis (other than concussion) - Have a pre-injury diagnosis of any of the following: depression, post-traumatic stress disorder, other psychiatric disorder - Taking any of the following medications: amantadine, , amphetamine, atomoxetine
|Official title||Transcranial LED Therapy for the Treatment of Chronic Mild Traumatic Brain Injury|
|Principal investigator||William P Meehan, MD|
|Description||Concussion, also known as mild traumatic brain injury (mTBI), results from a rotational acceleration of the brain. The biomechanical forces which cause concussion lead to the opening of ion channels within the neuronal cell membranes, allowing for a massive influx of sodium and efflux of potassium. This results in a spreading depression type of phenomenon, leading to the depolarization of neurons diffusely throughout the brain.19 In order to restore the homeostatic ion gradients across the membrane, the sodium-potassium pumps require increasing amounts of adenosine triphosphate (ATP). Thus, there is an increased need for ATP after concussion. ATP is supplied by the glycolysis of glucose from the blood stream. Both experimental models of concussion and human studies, however, show decreased cerebral blood flow after the initial response to injury. Thus, there is an increased demand for ATP after concussion; but a diminished supply of glucose to meet the demand. The absorption of light in the red/near infrared wavelength spectrum by cytochrome C oxidase increases ATP synthesis. Thus, by increasing ATP synthesis, red/near infrared LEDs can treat the underlying pathophysiological cause of concussion symptoms. If successful, this would be the first therapy to directly treat the underlying pathophysiology of concussion.|
Call for more information